Bimagrumab

Names

[ Name ]:
Bimagrumab

Biological Activity

[Description]:

Bimagrumab (Anti-ACVR2B Reference Antibody) is a human monoclonal antibody that blocks activin type II receptor (ActRII), with KDs of 1.7 pM and 434 pM for human ActRIIB and ActRIIA, respectively. Bimagrumab can be used for the research of pathological muscle loss and weakness[1][2].

[Related Catalog]:

Research Areas >> Metabolic Disease

[Target]

ACVR2B:1.7 pM (Kd)

ACVR2A:434 pM (Kd)

[In Vitro]

BYM338 (1 pM-1 μM; 24 h) 抑制 HEK293 细胞中 Myostatin 和 Activin A- 诱导的 Smad2/3 依赖性荧光素酶反应，IC50 值分别为 154 和 343[2]。 BYM338 (4 days) 可防止外源添加 Myostatin 或 Activin A 诱导的分化和融合抑制[2]。

[In Vivo]

BYM338 (6-20 mg/kg; 皮下注射，每周一次，持续 4 周) 促进所有检查肌肉的体重增加和骨骼肌肥大，包括慢速、快速和混合肌肉[2]。 BYM338 (5-20 mg/kg；皮下注射，每周一次，持续 14 天) 可防止糖皮质激素诱导的小鼠肌肉萎缩[2]。

[References]

[1]. Heymsfield SB, et, al. Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial. JAMA Netw Open. 2021 Jan 4;4(1):e2033457.

[2]. Lach-Trifilieff E, et, al. An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy. Mol Cell Biol. 2014 Feb;34(4):606-18.

Chemical & Physical Properties

No Any Chemical & Physical Properties